CTLA4 and neoplasm: Combination of ICBs (including anti-PD-L1, anti-PD-1 and anti-CTLA-4) and MK2206 significantly inhibited tumor growth in 4T1, B16-F10 and mGSC cell lines and prolonged survival in B16-F10 and mGSC cell lines (Fig. 6g–o).